The Defense Medical Materiel Program Office (DMMPO) Medical Materiel Enterprise Standardization Office (MMESO) announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of Nasopharyngeal Airways. The MMESO South is the lead MMESO for this project.
The primary objective of this program is to standardize the quality of care across the MMESO North, South, West, Pacific, Europe (hereafter referred to as MMESOs) areas of responsibility (AOR) and operational assemblages based on the critical balance of clinical efficacy and value. This Standardization Action (SA) will apply to all MMESOs. It is intended for this initiative to result in the standardization of a technically and clinically preferred product (s) and source for institutional and operational medicine requirements at the best possible price. It is intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). It is also intended that standardized products be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance requirements as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical the clinical preferred threshold, best price will determine selection. It is intended that the selected vendor (s) for this SA support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. The government is seeking a single award for this SA.
The major facilities in the MMESOs include, but are not limited to MMESO North: Walter Reed Army Medical Center, National Naval Medical Center, Naval Medical Center Portsmouth, Wright-Patterson Medical Center; MMESO South: Wilford Hall Medical Center, Brook Army Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital; MMESO West: Naval Medical Center San Diego, Madigan Army Medical Center, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific: Tripler Army Medical Center, Honolulu, HI, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe: Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, the 48th Medical Group, Lakenheath, UK; and Operational U.S. Forces.
This standardization action is part of the Medical/Surgical PV program executed by the Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel. To participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the current Med-Surg PV for each MMESOs Area of Responsibility (AOR), i.e., Cardinal Health, and Owens & Minor. This requirement is pursuant to the DAPA clause by which DAPA holders agree to the standardization process and agree to allow PVs to distribute their products. The Incentive Agreement (IA) resulting from this RFIAQ is a supplement to the PV Program and is not a contract. For additional information regarding DLA Troop Support Medical's PV program please access its web site at https://dmmonline.dscp.dla.mil

This IA standardization initiative will be a Three Phase IPP Process: vendor (s) who meets the technical / company requirements in Phase I will be invited to advance and participate Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be run concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is August 2011. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost) will determine selection. Points of Contact: Mr. Kevin Hill, MMESO South, Team Leader, [email protected], 210-292-3270; Mr. Jim Quinn, Clinical Analyst, [email protected], 210-292-3295.

B. Products & Performance Required
The MMESOs, are seeking product line items in the category of Nasopharyngeal Airways. Within the MMESOs, this product line has an estimated annual dollar requirement of $1,855,661.91. This forecast is based on historical Prime Vendor sales during a recent 12-month period. Based on the recent 12-month usage data 15 clustered line items of the total 115 line items, account for 99.25% ($1,841,758.94) of the total volume in sales ($1,855,661.91) in the MMESOs and are procurement significant. The top high volume usage lines for this project are shown in the Technical/Company Requirements below, consolidated by product type to reduce duplication within the top 15 lines. This represents the line item, or SKU, reduction that is an additional objective of this program.

C. Instructions to Vendors
A vendor interested in participating in this standardization initiative will provide an initial response to the FBO-posted RFIAQ to Mr. Kevin Hill, MMESO South, Team Leader, [email protected], 210-292-3270; Mr. Jim Quinn, Clinical Analyst, [email protected], 210-292-3295. The vendor's initial responses will include detailed information requested in the technical/company requirements listed in the FBO RFIAQ and must also include: (1) Company name and address; (2) Company Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address); and (3) Identification of the RFIAQ to which the vendor is responding. Due to the potential for e-mail to be lost in transmission, from network security, etc., vendor is strongly encouraged to confirm with the MMESO South that its initial submission, quote and literature actually arrived at the MMESO South via email. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. A vendor who does not meet the deadline of COB 5:00PM Central Standard Time (CST) on the date listed for closing (per the FBO RFIAQ), will be disqualified from further consideration in the standardization initiative.

D. Source Selection Procedures
The MMESO Tri-Service Product Review Board (TPRB) will serve as the forum for clinical recommendations for product selection, seeking and evaluating opportunities for committed volume purchase agreements, and coordinating logistics efforts in support of DoD Components. The boards are chaired by Designated Senior Logisticians (DSLs) and co-chaired by Designated Senior Clinicians (DSCs) in the MMESO AORs and include clinicians and logisticians for Medical Treatment Facilities (MTFs) within each MMESO. The Clinical Advisory Committee (CAC) members are the deciding officials for this initiative. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. The MMESO South reserves the right to conduct discussions and request revised quotes, if determined necessary.

Phase I Technical / Company Requirements
The MMESO CPT will review the responses from the vendors and determine which vendors meet the technical/company requirements and determine acceptability. A vendor must meet the technical requirements for continued consideration in this initiative. A vendor who does not meet the requirements will be disqualified. Failure to provide any requested information or meet any of the technical requirements will disqualify the vendor from further consideration. A vendor who meets the following technical/company requirements will be qualified/invited to participate in the clinical/performance selection and will be requested to submit their best product/price discount quotes via an email communication. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) should be digitally signed.

Technical/Company Requirements: During the acquisition planning process, the MMESO CPT validated/approved the technical/company requirements outlined below. The seven requirements below must be answered with the vendor's initial submittal by the response date stated in the FBO announcement:

1. Vendor MUST provide a line of Nasopharyngeal Airways products that includes at a minimum the specific products and sizes identified below in the table for Nasopharyngeal Airways. Vendor MUST provide a complete itemized list of items supplied (manufactured and/or distributed by brands and descriptions) via excel sheet, and product catalog & literature in response to this RFQ with initial submittal. Vendor is required to supply all items listed in all sizes and device type. Vendor is required to supply all items listed in all sizes listed and will include at a minimum:

Item Description
Nasopharyngeal Airways 12F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 12F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 12F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 14F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 14F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 14F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 14F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 16F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 16F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 16F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 18F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 18F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 18F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 18F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 19F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 20F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 20F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 20F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 20F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 22F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 22F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 22F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 22F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 23F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 24F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 24F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 24F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 24F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 26F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 26F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 26F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 26F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 28F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 28F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 28F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 28F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 29F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 30F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 30F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 30F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 30F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 32F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 32F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 32F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 32F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 34F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 34F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 34F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 34F Adjustable Flange Disposable, Sterile Neoprene
Nasopharyngeal Airways 36F Adjustable Flange Disposable, Sterile Latex
Nasopharyngeal Airways 36F Adjustable Flange Disposable, Non-Sterile in Latex
Nasopharyngeal Airways 36F Adjustable Flange Disposable, Sterile PVC
Nasopharyngeal Airways 36F Adjustable Flange Disposable, Sterile Neoprene
* Operational usage items are included in this list of Nasopharyngeal Airways.

2. Vendor MUST have a DAPA or be in the process of obtaining a DAPA for the Nasopharyngeal Airways product line. Vendor MUST provide the DAPA number with initial submittal or provide documentation that DAPA has been applied for with response submittal.
3. Vendor MUST have agreements with the current Med/Surg Prime Vendors for each MMESO AOR, i.e. Cardinal Health and Owens & Minor for Nasopharyngeal Airways or be in the process of obtaining Prime Vendor agreements. Vendor must provide documentation to support agreements with initial submittal.
4. Vendor MUST submit discounts off DAPA for the products included in this standardization initiative. Vendor that fails to submit a discount from DAPA will be disqualified. Where lower FSS prices are available, DAPA holder is required by previous agreement to provide the FSS price as the DAPA price. Vendor shall not quote FSS prices as the discounted price for purposes of this standardization initiative.
5. Vendor must provide Nasopharyngeal Airway products that are approved for use by American Society of Anesthesiology Standards, Guidelines and Policies in all clinical settings and ANSI/ISO 5364 as an American National Standard, and provide literature to support this requirement with the initial submittals.
6. Vendor must supply "instructions/directions for use" for all products to be supplied along with the product literature submitted in response to this RFQ.
7. Vendor must be able to provide products that are Single use, disposable, latex-free. Vendor must ensure that all such Single use, disposable, latex-free products are clearly labeled as such on all exterior and interior packaging. Vendor must provide descriptions of the labeling with the initial submittal.

Phase II Acceptability Evaluation Clinical Performance
Clinical Performance Requirements
Following acceptability of the technical/company requirements, the MMESO South, on behalf of the CPT, will request product sample sets from the product group to be sent to the CPT members at the participating MTFs. Vendor will be given 30 calendar days from the issue of the notice in which to deliver the product samples for clinical evaluation at Phase II. Product samples must be shipped to arrive at the designated addresses by 5:00PM local time for each MTF on the 30th calendar day after the notice to ship. Vendor MUST be able to deliver product literature, training materials and evaluation samples to the MMESO Pacific via FedEx or UPS AND to the MMESO Europe via United States Postal Service (USPS) and throughout the United States when requested in Phase II. Vendor who cannot or does not meet this requirement will be disqualified from the standardization process. Vendor must send the MMESO South verification regarding the shipment of literature and samples. This information will include the date of shipment, final delivery date, tracking numbers and the carrier used by the vendor. Vendor will provide from the following list no cost product samples for clinical/performance evaluation. Each POC evaluating products will select two (2) sizes from the list below (based on their specific clinical requirements) and will evaluate two each of those sizes. Vendor will only provide sample products of the items that are requested and being evaluated. (Unused samples will not be returned).

Item to Send Number Each to send Size Material Description
Adjustable Flange Nasopharyngeal Airway 2 12Fr/4.0mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 14Fr/4.3mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 16Fr/5.3mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 18Fr/6.0mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 20Fr/6.7mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 19Fr/ Sterile in PVC
Adjustable Flange Nasopharyngeal Airway 2 22Fr/7.3mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 23Fr/7.7mm OD Sterile in PVC
Adjustable Flange Nasopharyngeal Airway 2 24Fr/8.0mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 26Fr/8.7mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 28Fr/9.3mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 29Fr/9.7mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 30Fr/10.0mm OD Sterile in PVC
Adjustable Flange Nasopharyngeal Airway 2 32Fr/10.7mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 34Fr/11.3mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene
Adjustable Flange Nasopharyngeal Airway 2 36Fr/12.0mm OD Sterile & Non-Sterile in either Latex, PVC or Neoprene

The clinical/performance acceptability evaluation period will last for fourteen (14) calendar days. The acceptability evaluation responses will be in a Likert scale format with a one (1) through five (5) scoring range. The scale descriptors are: one (1)- Completely Unacceptable, two (2)- Overwhelmingly Unacceptable, three (3)- Partially Unacceptable, four (4)- Acceptable, and five (5)- Highly Acceptable. The MMESO TPRB has established a 4.0 as the Clinically Preferred threshold of products for standardization.
A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. Of those vendors who are qualified as clinically preferred, selection will be based on best price. A vendor who has been disqualified will be notified in writing upon disqualification. Clinical /performance acceptability evaluations by the participating CPT facilities will be tabulated resulting in one score per participating MMESO per vendor. The participating MMESOs' scores by vendor will then be combined resulting in one final vendor performance evaluation score. All clinical/performance acceptability evaluations will be tabulated by the MMESO South, and results will be forwarded to the MMESO CPT for final review. Each MTF will evaluate the Nasopharyngeal Airways products with the below listed requirements. Each MTF will provide a minimum of two evaluations per vendor in a clinical/patient setting.

There will be approximately 12 MTFs enterprise wide that will be evaluating products.

Clinical/Performance Requirements: During the acquisition planning process, the MMESO CPT validated/approved the clinical/performance requirements outlined below.
1. Airway size is easy to identify. The evaluator will hold the airway between thumb and forefinger and will be immediately able to visualize the size on the product and/or packaging.
2. Airway has smooth rounded edges. The airway should have smooth rounded edges and be soft and flexible to reduce risk of tissue damage to patient.
3. Airway facilitates oralpharyngeal suctioning. The evaluator will observe the critical function of suctioning for patient airway maintenance.

Phase III Pricing Analysis
Price Analysis
Upon completion of the Phase I - Technical/Company Requirements, a vendor who is found technically acceptable will be qualified /invited to provide product samples and price discount quotes concurrently. A vendor will be given 30 calendar days from the date of pricing requests, to submit IA pricing quotes, in a prescribed electronic spreadsheet format, based upon the requirements of the MMESOs. Pricing will be submitted to MMESO South and must be received by 5:00 PM CST, thirty (30) calendar days after the issue date of the vendor notice to submit best price quotes. Vendor quotes should contain the vendor's best product matches for the specific products requested in this announcement. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing for the products identified in this announcement (based on committed volume of 80% of the total requirements of the MTFs in the MMESOs). Price will be analyzed based on the projected Aggregate Post-Standardization costs for each vendor. Aggregate Post-Standardization Cost will be calculated for each vendor by applying the vendor's offered prices to the anticipated annual usage of the enterprise. Unmatched items will be represented in the Post-Standardization Cost at a baseline non-discounted price (current DAPA price of product with highest procurement). Among the products and sources that were determined to be clinically preferred, the best price Aggregate Post-Standardization Cost will be selected.

 

Bid Protests Not Available